Specifically, despite being reliable for hemoglobinopathies, GALT and biotinidase enzymes as well as providing baseline testing for amino acids and acylcarnitines, admission testing may result in inaccurate TSH, 17-OHP, and cystic fibrosis (IRT) screening. This evidence concerns the gene BTD and hemoglobinopathy.